STAT

Skylark Bio kicks off new gene therapy trial for deafness

Biotech startups in the U.S., France, and China are racing to bring new gene therapies for deafness by targeting different genetic mutations.
STAT

Nurses seek a seat at the table as they fight expanding clinical AI

Katie covers the impact of health technology on patients, clinicians, and businesses. Her stories explore the price tag of clinical AI, digital health at the FDA, and the boom in direct-to-consumer ...
Opinion
STATOpinion

IRBs have a problem. Can North Star’s nonprofit model save it?

As institutional review boards face pressure from companies and ethicists, North Star Review Board offers a nonprofit model as more independent.
STAT

Pharmalittle: We’re reading about an FDA rejection, 340B court battles, and more

Ed’s stories explore prescription drug pricing, affordability and access, as well issues surrounding patents, litigation, and legislation. He is also the author of the morning Pharmalittle newsletter ...
STAT

FDA to require notice of additives in food supply for the first time

RFK Jr. is claiming a win with a new proposal on the food industry's GRAS loophole; nutrition advocates give mixed reviews.
STAT

Trump returns to controversial vaccine policy with order questioning childhood schedule

The Trump administration, which had recently avoided public discussions of vaccine policy because of concern around the political repercussions, is changing course.
STAT

In surprise decision, FDA rejects radiopharma therapy expected to rival Novartis treatment

The FDA has rejected a radiopharmaceutical therapy because of manufacturing issues, halting what would have been a competitor for Novartis.
STAT

Sionna’s experimental cystic fibrosis pill falls flat in mid-stage trial

Jason is a general assignment reporter, with particular focus on genetic medicine and rare disease. Confidential tips can be sent on Signal at JasonMast.77. Sionna Therapeutics said Monday that its ...
STAT

Silence Therapeutics aims at Takeda with new data in rare blood cancer

Jason is a general assignment reporter, with particular focus on genetic medicine and rare disease. Confidential tips can be sent on Signal at JasonMast.77. An experimental medicine from Silence ...
STAT

Heart failure drug from Tenax Therapeutics fails in pivotal study

Adam Feuerstein, a senior writer and biotech columnist, is the author of Adam’s Biotech Scorecard, a subscriber-only newsletter about the crossroads of drug development, business, Wall Street, and ...
STAT

Pharmalittle: We’re reading about a Sanofi drug shortage, a Jazz Pharma deal, and more

Ed’s stories explore prescription drug pricing, affordability and access, as well issues surrounding patents, litigation, and legislation. He is also the author of the morning Pharmalittle newsletter ...
STAT

FDA panel to weigh Grail’s Galleri test

China reins in its biotech innovation engine, radiopharma boom meets unexpected hurdles, and more news from The Readout ...